Overview

New Nasal Applicator / New Formulation - User Study

Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide